Advertisement

EGFR and Its Role in Colorectal Cancer

  • Saimila Momin
  • Ganji Purnachandra NagarajuEmail author
Chapter

Abstract

Colorectal cancer is one of the most common and fatal types of cancers which congregates in the colon or rectum regions of the body. One of the ligand-receptor complexes that plays a major role in the progress of colorectal cancer includes the epidermal growth factor receptor (EGFR). EGFR is expressed on the cellular surface of a variety of cells such as epithelial and muscle cells. Upon binding to a ligand, the overall EGF-EGFR complex leads to a cascade of signaling within the cell to ultimately allow for multiple cellular functions including proliferation, differentiation, and dedifferentiation. When the EGFR activation is overexpressed, it can lead to colorectal cancer. Currently, there are many investigations aiming to study how the complex can be manipulated especially through inhibitors and antibodies to reverse the advancement of colorectal cancer. This chapter aims to understand the EGF-EGFR complex and explore the current research studies investigating EGFR and its role on colorectal cancer.

Keywords

EGF EGFR Colorectal cancer 

References

  1. 1.
    What Is Colorectal Cancer? (n.d.) Retrieved October 10, 2017, from https://www.cancer.org/cancer/colon-rectal-cancer/about/what-is-colorectal-cancer.html
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29CrossRefGoogle Scholar
  3. 3.
    Cohen RB (2003) Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2:246–251CrossRefGoogle Scholar
  4. 4.
    Pabla B, Bissonnette M, Konda VJ (2015) Colon cancer and the epidermal growth factor receptor: current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol 6(5):133–141.  https://doi.org/10.5306/wjco.v6.i5.133 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wells A (1999) EGF receptor. Int J Biochem Cell Biol 31:637–643CrossRefGoogle Scholar
  6. 6.
    Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164:769–779CrossRefGoogle Scholar
  7. 7.
    Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti A, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15–31.  https://doi.org/10.1517/14728222.2011.648617 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Krasinskas AM (2011) EGFR signaling in colorectal carcinoma. Pathol Res Int 2011:932932., 6 pages.  https://doi.org/10.4061/2011/932932 CrossRefGoogle Scholar
  9. 9.
    Spano J-P, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere J-F, Raphael M, Penault-Llorca F, Breau J-L, Fagard R, Khayat D, Wind P (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–108.  https://doi.org/10.1093/annonc/mdi006 CrossRefPubMedGoogle Scholar
  10. 10.
    Saif MW (2010) Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 19(3):357–369.  https://doi.org/10.1517/13543781003593962 CrossRefPubMedGoogle Scholar
  11. 11.
    Citri A, Yarden Y (2006) EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516.  https://doi.org/10.1038/nrm1962 CrossRefPubMedGoogle Scholar
  12. 12.
    Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Braud FD (2007) First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 110(4):752–758.  https://doi.org/10.1002/cncr.22851 CrossRefPubMedGoogle Scholar
  13. 13.
    Takahashi M, Wakabayashi K (2004) Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 95:475–480CrossRefGoogle Scholar
  14. 14.
    Dougherty U, Mustafi R, Valuckaite V, Konda VJ, Pekow J, Sadiq F, Haider HI, Adhikari S, Hart J, Joseph L et al (2015) Western diet up-regulates ADAM17, a key meditator of EGFR signaling via activation of colonic renin-angiotensin system and inhibition of miR-145,-148a and -152. Gastroenterology 148:S–99Google Scholar
  15. 15.
    Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Sikic BI (2008) A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res 14(21):7074–7079.  https://doi.org/10.1158/1078-0432.ccr-08-1014 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nicholson R, Gee J, Harper M (2001) EGFR and cancer prognosis. Eur J Cancer 37:9–15.  https://doi.org/10.1016/s0959-8049(01)00231-3 CrossRefGoogle Scholar
  17. 17.
    Yarom N, Jonker DJ (2011) The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 11(57):95–105PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Hematology and Medical Oncology, Winship Cancer InstituteEmory UniversityAtlantaUSA
  2. 2.Department of Hematology and Medical Oncology, School of Medicine, Winship Cancer InstituteEmory UniversityAtlantaUSA

Personalised recommendations